Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis.

Abstract

A 75-year-old male with compensated Child-Pugh B cirrhosis initiated sofosbuvir plus simeprevir, and developed hepatic decompensation and died a few days thereafter. High exposure to simeprevir leading to hepatotoxicity most likely explained this fatal outcome. This observation, along with similar cases recently reported in the literature, should raise awareness of the potential for decompensation in patients with advanced cirrhosis treated with simeprevir.

• Authors: Vincent Soriano, Pablo Barreiro, Carmen de Mendoza, José M Peña
• Journal: Antiviral therapy (Antivir Ther) Vol. 21 Issue 1 Pg. 91-2 ( 2016) ISSN: 2040-2058 [Electronic] England
• PMID: 26042495 (Publication Type: Case Reports, Letter, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Simeprevir
• Sofosbuvir

Topics

• Aged
• Antiviral Agents (adverse effects, therapeutic use)
• Hepatitis C, Chronic (complications, diagnosis, drug therapy, virology)
• Humans
• Kidney Function Tests
• Liver Cirrhosis (diagnosis, etiology, physiopathology)
• Liver Function Tests
• Male
• Severity of Illness Index
• Simeprevir (adverse effects, therapeutic use)
• Sofosbuvir (adverse effects, therapeutic use)
• Treatment Outcome